Parallel Session 10: APS

29 ANTIHOSPHELIPID SCORE IS A NOVEL RISK FACTOR FOR IDIOPATHIC OSTEOENEOSIS

N Ohnishi*, M Kato, Y Ogata, S Abe, M Kono, Y Shibata, S Tanimura, R Hisada, M Doi, Y Fujieda, K Oku, T Bohgaki, O Amengual, S Yasuda, T Atsumi. Hokkaido University Graduate School of Medicine, Division of Rheumatology. Endocrinology and Nephrology, Sapporo, Japan

Background and Aims Our group introduced a quantitative marker of antiphospholipid antibodies (aPL) “antiphospholipid score (aPL-S)”, which well reflected the risk of developing thrombosis (Otomo K, et al. Arthritis Rheum 2012). Idiopathic osteonecrosis (ION) has been shown to occur as a result of ischemia, however, the involvement of aPL in its pathophysiology remains to be elucidated. In this study, we aimed to identify the impact of aPL on the development of ION using aPL-S.

Methods A single centre retrospective study comprising 75 consecutive patients with systemic lupus erythematosus who underwent magnetic resonance imaging of hip joints from January 2000 to March 2016. aPL-S, as well as classical risk factors for ION, were evaluated in all the enrolled patients.

Results ION of the femoral head was observed in 33 out of 75 patients (44%). High aPL-S (p=0.009), aPL positivity (p=0.009), male (p=0.007), malar rash (p=0.010) and high dose (>0.8 mg/kg/day) glucocorticoids (p<0.001) were identified as risk factors for ION at univariate analysis. Multivariate analysis confirmed high aPL-S, male, malar rash and high dose glucocorticoids as independent variables. Six out of 8 patients (75%) with very high aPL-S (>30), developed ION. Conversely, systemic lupus erythematosus disease activity index and pulse methylprednisolone therapy were not identified as risk factors for ION.

Conclusions We newly identified aPL-S as a risk factor for ION. ION should be considered as one of the antiphospholipid antibody-associated-disease.

Parallel Session 11: Effector T cells in SLE

30 METABOLIC REPROGRAMMING IN CD4+CD28- CXCR3INT-BETHI CELLS AND ITS RELEVANCE TO PATHOGENESIS IN PATIENTS WITH SLE

1S Iwata*, 2K Sakata, 3M Hajime, 4M Zhang, 13M Torigoe, 1N Ohkubo, 5S Nakayamada, 6Y Tanaka. 1University of Occupational and Environmental Health, The First Department of Internal Medicine, Kitakyushu, Japan; 2Department of Endocrinology- Metabolism-Rheumatology and Nephrology, Faculty of Medicine- Oita University- Yufu- Oita- Japan; 4Yufu, Japan

Background and Aims CD4⁺ T cells play a crucial role in pathological process of Systemic Lupus Erythematosus (SLE). Recently, we found that T-bet is an important factor for shift to glycolysis in activated CD4⁺ T cells in vitro. In this study, we examined the mechanism by which T-bet in CD4⁺ T cells involved in pathogenesis of SLE.

Methods Peripheral blood mononuclear cells were obtained from 19 healthy controls (HCs), 30 patients with bio-naïve active RA and 60 patients with SLE. The expression of CXCR3, T-bet, mTORC1 phosphorylation and IFN-γ production in CD4⁺ T cells were measured by flow cytometry, and assessed the association with clinical characteristics.

Results We found that the ratio of CD28⁺CXCR3⁺⁺T-bet⁺⁺ cells in patients with SLE was significantly higher compared to HCs. CD4⁺CD28⁺CXCR3⁺⁺T-bet⁺⁺ cells mainly consisted of CD45RA-CCR7- effector memory cells and were significantly activated with pronounced IFN-γ production. Interestingly, the ratio of CD4⁺CD28⁺CXCR3⁺⁺T-bet⁺⁺ cells was significantly correlated with the number of immunosuppressants previously used for the SLE patients, that is treatment-resistant. Phosphorylation of mTORC1, which is important for shift to glycolysis, in CD4⁺ T cells from patients with SLE was significantly increased compared to HCs. T-bet expression was significantly correlated with mTORC1 phosphorylation and IFN-γ production in CD4⁺ T cells from patients with SLE.

Conclusions These results indicated that CD4⁺CD28⁺CXCR3⁺⁺T-bet⁺⁺ cells might be related to refractory to established therapies in patients with SLE. In addition, these cells are constitutively activated accompanied with shift to glycolysis through IFN-γ-mTORC1-T-bet pathway, which is a potential target for patients with SLE.

Parallel Session 15: Pearls in autoimmunity

31 HARNESSING AUTOIMMUNITY (DISEASE-SPECIFIC AUTOANTIBODY AND ITS VARIANT) IN THERANOSTICS OF DISEASE

1E Matsuura*. 2Okayama University, Collaborative Research Centre and Department of Cell Chemistry, Okayama, Japan

The prevalence of autoimmune disorder or disease is characterised by its targeting autoantibodies. The term “theranostic”, an innovative concept of medical modality featuring a portmanteau of therapeutic and diagnostic systems, was coined in 2002 and has since undergone progressive development into current preclinical stages. Recently, we have prepared humanised and shortened variants of IgG (single chain variable fragment; 25 kDa-scFv) targeting towards: (i) β2-glycoprotein I (β2-GPI) complexed with oxidised LDL, a key population of pathogenic autoantibodies related to the development of antiphospholipid syndrome (APS) and autoimmune mediated atherosclerosis; and (ii) mesothelin, a 40 kDa-tumour differentiation antigen, to establish a clinically applicable theranostic in autoimmune mediated atherosclerosis and oncology. Goals of our theranostic system (comprises of novel and biodegradable 89Zr-radiolabeled nanoparticles conjugated with specific scFv) are to successfully deliver therapeutically effective small interfering RNA (siRNA), for inducing apoptosis in targeted cells of experimental models and to offer simultaneous visualisation of the targets via PET imaging system. The combination of photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) and photo-controlled intracellular siRNA...